Partnering OpportunitiesBusiness development is a core part of Silence’s strategy.
The range of indications for Silence Therapeutics technologies extends well beyond our actual growing pipeline. We can aim at previously regarded "undruggable" targets, with the "classical" approaches (small molecules and biology), using Silence unique therapeutics RNAi therapeutics platform. Silence Therapeutics is commercializing its platform both through an active technology partnering strategy and by licensing its own therapeutic programs at the appropriate stage of development.
We welcome the interest from pharmaceutical and biotechnology companies seeking access to our proprietary RNAi and delivery technology platform or to our therapeutic pipeline.
There are various opportunities to partner with Silence Therapeutics as we look on to:
- Form new collaborative alliances with Pharmaceutical and Biotechnology partners
- Grant access to our proprietary AtuRNAi® technology
- Grant access to our proprietary delivery technologies, AtuPLEX®, DACC and DBTC
- Out-license/co-develop internal candidates
For more information on outlicensing or partnering opportunities, please contact: firstname.lastname@example.org